This cross-sectional study examines the association between total prescription medication use and potentially inappropriate medication use (PIRx) among community-dwelling elderly patients with and without dementia. Data (
A n objective of Healthy People 2010 is ensuring safe and effective use of medical interventions among all older adults. Prescribing for elderly patients with dementia can be challenging because of the changing needs associated with cognitive decline and related behavioral and psychologic symptoms. 1 In addition, more medications may be indicated among elderly patients with dementia for treatment of coexisting health conditions common in the aging population. 2 Although taking many prescription medications (ie, polypharmacy) may be necessary for some individuals with complex illnesses, multiple medication use especially among elderly individuals can pose a significant risk for medication error, nonadherence, and adverse drug-drug interactions. 3 Epidemiologic studies have found that taking a large number of prescription medications is associated with the use of unnecessary or inappropriate medications. [4] [5] [6] Probably the most cited measure of potentially inappropriate medication use (PIRx), the Beers criteria contain medications that generally should be avoided among older adults because the health risks outweigh the benefits and because safer and/or more effective alternatives exist. 7, 8 The Beers criteria identify a list of medications associated with increased adverse drug events and unnecessary hospitalization among elderly patients in ambulatory settings and nursing homes. 9 Most studies on polypharmacy and PIRx have focused either on the general elderly population or on elderly patients with dementia living in residential care settings. Little is known, however, about prescription medication use in elderly persons with dementia residing in the community. As many of these individuals with dementia are at the threshold of institutionalization, 10 examining the quality of medication use in this population is particularly significant because both polypharmacy and PIRx may predispose them to conditions correlated with nursing home placement such as falls and behavioral symptoms. 11, 12 Using data from the National Alzheimer's Coordinating Center Uniform Data Set (UDS), one of the most comprehensive tools currently available for investigating patients with dementia across the United States, this study examines the total number of prescription medications used and its association with PIRx in community-dwelling elderly patients with and without dementia. 16 ]; and a predetermined list of comorbid conditions. The study sample included elderly individuals with and without dementia. To identify subjects with dementia, we first included 3212 community-dwelling individuals aged 65 years and above who met ''the standard criteria for dementia of the Alzheimer type or for other non-Alzheimer dementing disorders'' as judged by a trained ADC clinician, and had CDR global scores ranging from 0.5 to 3.0 (very mild to severe dementia). Community-dwelling individuals were those living in an independent family residence or retirement community. Of the 3212 individuals, we excluded the following 547 (17%) persons (not mutually exclusive): 415 with no reported data on prescription drug use, 118 with no accompanying informant present during their visit, and 85 with an informant deemed ''unreliable'' by ADCs' clinicians. The remaining 2665 elderly patients with dementia were included into our study.
METHODS

Data Source and Study Sample
To identify subjects without dementia (control cases), we included 2513 community-dwelling elders aged 65 years and above who did not meet the standard criteria for dementia as judged by a trained ADC clinician, had CDR global score of 0 (no cognitive impairment), and had Functional Activities Questionnaire total score of 0 (no executive functional impairment related to cognition, such as the ability to shop, cook, and pay bills). Of these 2513 individuals, we excluded the following 660 (26%): 641 with no reported prescription drug use and 19 with reported use of currently Food and Drug Administration-approved medications for treatment of Alzheimer disease. In summary, the study sample that met the inclusion criteria included 4518 subjects: 2665 with dementia (59%) and 1853 without dementia (41%).
Of the 4518 study subjects, 4087 (90%) had complete data: 2467 subjects with dementia and 1620 subjects without dementia. See Statistical Analysis section for discussion on sensitivity analysis of missing data. Approval from the Northwestern University's Institutional Review Board was obtained at the start of this study.
Measures
Total Number of Prescription Medications Used
The total number of prescription medications used was counted per patient for routinely scheduled medications (not ''as-needed'' or over-the-counter), excluding vitamins, herbal supplements, and topical agents. The variable was categorized as 1 to 2, 3 to 4, 5 to 6, 7 to 8, and 9 or more.
Potentially Inappropriate Medication Use (PIRx)
Beers 2003 criteria identified 3 types of PIRx: (1) medications that generally should be avoided among any elderly patients, (2) medications at a specified dose that should not be exceeded for any elderly patients, and (3) medications that should be avoided among certain elderly patients with specific comorbid conditions. 8 Owing to the nature of the data captured in the UDS, this study could not examine medications in the Beers criteria that had dosage specifications or that needed specific patient comorbid conditions. Therefore, PIRx was defined using a partial list of medications in the Beers 2003 criteria that included 44 agents/drug classes that should be avoided among all elderly patients regardless of health conditions, including dementia. Person-level dichotomous variables were constructed indicating whether PIRx occurred by matching the names and formulations of all medications taken by the subject with medications listed in the Beers criteria.
Subject Characteristics
Subject characteristics and their categorization are listed in Table 2 . Age was calculated based on date of birth and date of initial visit. Race/ethnicity was combined into 1 variable based on separate questions regarding race and Hispanic/Latino origin. Level of dependence was assessed with a question asking whether the subject was able to live independently, needed help with complex or basic activities of daily living, or was completely dependent on others.
Using the NPI-Q, we assessed the following 8 neuropsychiatric symptoms: agitation, irritability, depression, anxiety, motor disturbance, disinhibition, delusions, and hallucinations. A factor analysis indicated that there were 4 factors with 2 symptoms clustered within each: (1) agitation and irritability, (2) depression and anxiety, (3) motor disturbance and disinhibition, and (4) delusions and hallucinations. Therefore, the 8 neuropsychiatric symptoms were recategorized as the 4 factors (score range: 0 for no symptoms to 6 for severe in both symptoms) and each factor was analyzed accordingly in subsequent statistics analyses.
Dichotomous variables were created for 7 health conditions based on coexisting diagnoses, procedures, and conditions captured in the UDS (''yes'' if at least 1 was active or recent; ''no'' if otherwise): hypertension, hypercholesterolemia, incontinence (urinary or bowel), cardiovascular disease (heart attack, atrial fibrillation, angioplasty, cardiac bypass procedure, pacemaker, congestive heart failure, or other cardiovascular disease), thyroid disease, diabetes, and cerebrovascular disease (stroke, transient ischemic attack, or other cerebrovascular disease).
Severity of dementia was determined using the CDR global score, which summarized the degree of impairment in subjects' memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Although the Mini-Mental State Examination was available in the UDS, it was not used since it has been documented to yield potential false-positive scores among individuals with advanced age and high education. 17 Likely cause of dementia was the primary diagnosis based on clinician assessment: probable and possible Alzheimer disease, Lewy body dementia, frontotemporal dementia, Parkinson disease, vascular dementia, primary progressive aphasia, and all others.
Statistical Analysis
Bivariate analyses (Pearson w 2 and Wilcoxon tests) examined the distributions of subject characteristics and total number of medications used according to dementia diagnosis and PIRx (among subjects with dementia, PIRx vs. no PIRx; among subjects without dementia, PIRx vs. no PIRx) when aggregated over each ADC. The significance levels were not adjusted for multiple comparisons, but the P values from these tests were stratified by those attaining 0.05 and 0.001 significance levels which would correspond to performing 50 tests (Bonferroni adjustment, 0.05/50 = 0.001). Generalized linear mixed effects models were applied to estimate the association between PIRx and total medication use, controlling for subject characteristics and ADC differences. To determine whether dementia diagnosis modified the relationship between total medication use and PIRx, an interaction between dementia diagnosis and total medication use was entered into the regression model.
Two secondary analyses were performed to further examine how robust the relationship between total medication use and PIRx was in different scenarios. First, preliminary analysis found that oral estrogens accounted for 22%, the highest proportion, of all PIRx cases and that the percentage of females with PIRx was disproportionately higher in subjects without dementia than in those with dementia (68% vs. 53%, P<0.001). We therefore performed a secondary analysis with a modified definition of ''PIRx,'' which excluded oral estrogens. Second, to determine the differential effect of the severity of dementia and the likely cause of dementia on PIRx, we performed a subset analysis by limiting the study sample to only patients with dementia.
Among the 4518 study subjects who met the inclusion criteria, 431 (10%) had an item nonresponse in a subset of covariates of interest. The missing data were stratified into 2 mutually exclusive subject groups, those missing a demographic/subject characteristic variable (n = 97) and those missing all NPI-Q items (n = 334). Subjects missing a demographic/subject characteristic variable were excluded from all analyses. The subjects without NPI-Q were excluded from the primary and secondary analyses (discussed above), but a best/worst case sensitivity analysis was performed to assess the impact of their exclusion. The analysis entailed repeating previous regression models by adding missing NPI-Q items with imputed values of extreme scores. All analyses were performed using R-version 2.7.0. 18 Table 1 shows the 4087 subjects with complete data and their distribution of the total medication use, PIRx, and subject characteristics by dementia diagnosis and PIRx (additional data are available upon request). Elderly subjects with dementia on average took more medications (mean = 4.9; SD = 2.6) than those without dementia (mean = 3.9; SD = 2.5; P<0.001). Among subjects with dementia, those taking at least 1 PIRx on average took more medications (mean = 6.4; SD = 2.8) than those taking no PIRx (mean = 4.7; SD = 2.5; P<0.001). Similarly, subjects without dementia taking at least 1 PIRx on average took more medications (mean = 5.0; SD = 2.8) than those taking no PIRx (mean = 3.6; SD = 2.3; P<0.001).
RESULTS
Bivariate Analysis
Twenty percent (324/1620) of elderly subjects without dementia compared with 15% (372/2467) of those with dementia had at least 1 PIRx (P<0.001). The 5 most commonly used PIRx were similar between subjects with and without dementia: oral estrogens, muscle relaxants/ antispasmodics, fluoxetine, short-acting nifedipine, and doxazosin. Of all PIRx cases, oral estrogens accounted for the highest proportion (22%)-substantially higher than muscle relaxants/antispasmodics (14%), fluoxetine (13%), short-acting nifedipine (11%), and doxazosin (7%). When PIRx was redefined without oral estrogens, the proportions of PIRx became similar between both groups (14% of subjects without dementia and 13% of subject with dementia; P = 0.60).
Among subjects with dementia, more with PIRx were female, had lower education attainment, and had hypertension, incontinence, depression, and anxiety than those without PIRx. Among elderly subjects without dementia, more with PIRx were female, had at most high school degree, and had incontinence than those without PIRx. The distribution of dementia severity is as follows: very mild dementia (16.7%), mild dementia (27.2%), moderate dementia (12.0%), and severe dementia (4.4%). The 5 most common likely causes of dementia were probable Alzheimer disease (44.9%), possible Alzheimer disease (5.6%), Lewy body dementia (2.9%), frontotemporal dementia (1.7%), and Parkinson disease (1.2%). Table 2 presents 2 multivariate generalized linear mixed models based on complete cases that display the associations between subject characteristics and 2 definitions of PIRx: Model A-PIRx with oral estrogens, and Model B-PIRx without oral estrogens. Model A indicates that as total medication use increased from ''1 to 2'' to ''3 to 4,'' the odds of having PIRx (with oral estrogens) also increased (odds ratio = 2.85, 95% confidence interval = 2.12-3.83). The odds of having PIRx (with oral estrogens) continued to dramatically increase as total medication use increased, controlling for other subject characteristics. No significant interaction between dementia diagnosis and total medication use was observed; thus the interaction terms were excluded from the final model. Among the other subject characteristics, incontinence had significantly higher odds of having PIRx (with oral estrogens), whereas dementia diagnosis, male, hypercholesterolemia, cardiovascular disease, thyroid disease, and diabetes had lower odds.
Multivariate Analysis
Secondary and Sensitivity Analyses
Model B shows that as total medication use increased from ''1 to 2'' to ''3 to 4,'' the odds of having PIRx (without estrogen) also increased (odds ratio = 3.56, 95% confidence interval = 2.46-5.14). Similarly, the odds of having PIRx (without estrogen) continued to dramatically increase as total medication use increased. Although the significance of sex disappeared when oral estrogens were removed from the definition of PIRx, the significance of the other subject characteristics remained the same in the 2 models.
Furthermore, a regression model was estimated using only subjects with dementia (Table 3 ). Both models showed that whereas the odds of having PIRx (with and without oral estrogens) increased as total medication use increased, Lewy body dementia had lower odds of having PIRx wAmong the 4518 subjects who met the inclusion criteria, there were 4087 subjects (90.5%) with complete data. Of the complete cases, there were 2467 subjects with dementia (60.3%) and 1620 subjects without dementia (36.6%).
zAmong 2467 subjects with dementia, 374 (15%) had PIRx and 2095 (85%) had no PIRx. Bivariate analyses (Pearson w 2 and Wilcoxon tests) were performed to examine the difference in distributions of subject characteristics between those with PIRx and those with no PIRx.
yAmong 1620 subjects without dementia, 324 (20%) had PIRx and 1296 (80%) had no PIRx. Bivariate analyses (Pearson w 2 and Wilcoxon tests) were performed to examine the difference in distributions of subject characteristics between those with PIRx and those with no PIRx.
JNeuropsychiatric symptoms were assessed with the Neuropsychiatric Inventory-Questionnaire. Factors analysis identified 4 factors: (1) agitation and irritability, (2) depression and anxiety, (3) motor disturbance and disinhibition, and (4) delusions and hallucinations. Scores were summed according to the factors (score range: 0 = no symptoms to 6 = severe in both symptoms).
(with and without oral estrogens). In addition, controlling for other factors, the relationship between PIRx and severity of dementia was borderline statistically significant and inconsistent between the 2 models. In the sensitivity analysis, our findings from the complete cases were consistent with the best and worst case models.
DISCUSSION
This study uses the UDS data collected at 29 ADCs across the United States to examine total medication use and its relationship with PIRx among community-dwelling elderly subjects with and without dementia. Subjects with dementia generally have higher total prescription wRegression analyses were performed based on cases with complete data (N = 4087 patients). zNeuropsychiatric symptoms were assessed with the Neuropsychiatric Inventory-Questionnaire. Factors analysis was conducted and 4 factors were identified: (1) agitation and irritability, (2) depression and anxiety, (3) motor disturbance and disinhibition, and (4) delusions and hallucinations. Scores were summed according to the factors (score range: 0 = no symptom to 6 = severe in both symptoms).
CI indicates confidence interval.
medication use than those without dementia. As the total number of medications used increases, the odds of having PIRx substantially increases, regardless of dementia diagnosis and other subject characteristics. Our findings did not change after considering 2 definitions of PIRx (with or without oral estrogens) and accounting for missing NPI-Q data. Furthermore, these findings do not vary significantly by dementia severity or likely cause of dementia. Consistent with prior studies, [4] [5] [6] in which the estimated prevalence rate of PIRx as defined by Beers is about 20% in communitydwelling elders, our study provides further evidence that using many medications poses an elevated risk of PIRx.
Although taking many prescription medications may be necessary for some individuals, our findings raise important clinical concerns for elderly patients with dementia living in the community. More prudent care is warranted for this population because many of them are challenged by decreased decision-making capacity, problems with adhering to medications and reporting adverse effects, and unnecessary treatment burden for patients and their informal caregivers. 19 Furthermore, because polypharmacy and PIRx may significantly increase the risk of falls and adverse drug effects, prescribing unnecessary or inappropriate medications in elderly patients with dementia may further contribute to their risks for conditions associated with nursing home admission. Clinical decision-making regarding prescription medications for elderly patients with dementia and with other coexisting health conditions need to balance the potential health benefits and risks in light of the patients' overall health profile, existing drug regimen, and preferences. 20 Examining the relationship between total medication use and other measures of prescription quality such as PIRx is important for understanding the appropriateness of taking many medications, especially among vulnerable older populations. Recent evidence, however, suggests that polypharmacy may not be a straightforward indicator of the quality of medication use. In a study of 196 outpatients aged 65 years and above who were taking 5 or more medications, the incidences of both inappropriate use and underuse of medications were high, almost 65%. 21 Patients taking between 5 and 8 medications were more likely to be missing a potentially beneficial drug than taking an inappropriate medication, suggesting that decreasing the number of medications alone may not effectively improve the quality of medication use. Further investigation is needed to examine how generalizable those findings are to elderly patients with dementia.
As we examined a partial list of the Beers medications, the prevalence of PIRx reported here is likely to be conservative. Furthermore, in the absence of detailed clinical information, defining PIRx using the Beers criteria in this study may lead to some misclassification of inappropriate medication use. Certain clinical situations in elderly patients with dementia may warrant a particular Beers medication. For example, patients with Lewy body dementia are often sensitive to neuroleptics, yet there are reports of good response to subtherapeutic doses of antipsychotic medications when hallucinations and other behavioral problems are particularly problematic. 22 Nonetheless, the Beers criteria have identified some medications that should be avoided if at all possible even among elderly patients with dementia. For example, patients with Alzheimer disease are particularly sensitive to the cognitive impairments induced by drugs with anticholinergic properties, such as oxybutynin and tricyclic antidepressants. 23 Additional research may be necessary to examine more specific sets of medications to avoid for this population. Table 3 shows only 3 patient characteristics of interest: total medication use, likely cause of dementia, and dementia severity. Other variables adjusted for in the multivariate analysis include the following: age, sex, race, education, marital status, living arrangement, level of dependence, neuropsychiatric symptoms, and selected comorbidities.
zSeverity of dementia was assessed using the Clinical Dementia Rating scale (score range: 0.5 = very mild dementia to 3.0 = severe dementia. CI indicates confidence interval.
Since the publication of the Women's Health Initiative study trial, 24 prescriptions for oral estrogens have decreased dramatically in the general elderly female population. Surprisingly, this study found that the use of oral estrogens accounted for the majority of PIRx cases. According to the Beers 2003 criteria, oral estrogens can pose elevated risks of breast and endometrial cancer and had a lack of cardioprotective effect in older women. 8 Moreover, estrogen use has been associated with greater cognitive decline in postmenopausal women compared with placebo. 25 With no preferred alternatives within the same drug class, prescribing decisions should be made based on the risk-benefit ratio for oral estrogens to the individual patient.
Many medications in the Beers criteria have common adverse effects including confusion, nightmares, agitation, and depression that are similar to neuropsychiatric symptoms often accompanying progressive neurodegeneration among dementia patients. For example, fluoxetine can greatly increase the risk of excessive central nervous system stimulation, sleep disturbances, and agitation. 8 Muscle relaxants and antispasmodic agents can cause anticholinergic adverse effects and sedation. Elderly patients with dementia may be especially sensitive to these adverse drug effects because of physiologic and metabolic changes associated with aging. Making sound clinical decisions may be challenging in this population even for experienced clinicians who need to distinguish adverse drug-induced effects from associated symptoms of dementia when prescribing medications.
Although not the focus, this study finds that the risk of PIRx varies by coexisting health conditions, after controlling for total medication use and other characteristics. In particular, incontinence was associated with an increased risk of PIRx perhaps because muscle relaxants/antispasmodics being the second most commonly used PIRx in the study sample are prescribed to treat incontinence. More research is needed to understand the mechanisms underlying these prescribing patterns.
There are additional limitations to this study. First, the UDS does not contain data from a randomized national sample of patients; therefore, the generalizability of these findings to all community-dwelling elderly patients with dementia will need to be further examined. Patient recruitment into ADCs may bias the UDS data toward more educated, higher income elders who received tertiary care from NIA-funded centers. This selection bias may also explain our finding that after controlling for total medication use, elderly patients with dementia had a lower risk of PIRx than those without dementia. It is possible that our findings may reflect better prescribing practices, besides total medication use, than those occurring in the community. Second, despite having standardized protocol in data collection, the UDS relies on data entry at each ADC center that can lead to variation in data quality. Statistically, we have controlled for center effects to minimize potential bias in regression analyses. Third, because patients and proxy informants were asked to report patients' medication use, there is potential bias toward an underestimate of medication use. Finally, because of the cross-sectional and nonexperimental design of this study, causal relationships between polypharmacy and PIRx cannot be assumed. Although it is possible that taking many medications may increase the risk of PIRx, having PIRx may also increase the risk of taking many medications because of potential adverse events that require medical treatment. Although not a limitation, caution should be used to interpret estimates because of the large sample in this study. Some of the statistically significant associations that were observed between patient characteristics and PIRx (eg, age in Model A) may not be clinically meaningful.
In light of the significant risks for institutionalization among elderly patients with dementia, ensuring appropriate and safe medication use in this population is clinically important. This study provides additional evidence that a high volume of medication use (ie, polypharmacy) is associated with elevated risks of PIRx among ADC's community-dwelling elderly patients with dementia. Prescribing physicians should continuously evaluate the necessity and appropriateness of all drug therapies prescribed according to best practices and patients' goals of care.
